Bioretec
-
Regulatory
Bioretec updates its estimate of the timing for approval of the CE mark for the RemeOs™ trauma screw
TAMPERE, Finland, Nov. 4, 2022 /PRNewswire/ — Bioretec Ltd, a pioneer in biodegradable orthopedic implants, expects the European marketing authorization for the RemeOs™…
Read More » -
Extremities
Bioretec updates estimate of U.S. registration of RemeOs™ screws and expects approval in April 2023
TAMPERE, Finland, Oct. 14, 2022 /PRNewswire/ — Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, continues to discuss the company’s RemeOs™ trauma…
Read More » -
Regulatory
Bioretec’s hybrid composite patent has been approved in Europe
TAMPERE, Finland, Sept. 8, 2022 /PRNewswire/ — The European Patent Office has announced to approve Bioretec Oy’s hybrid composite material patent application EP3782657A1…
Read More » -
Extremities
Bioretec’s ActivaPin™ bioresorbable implant provides good alternative treatment of pediatric elbow injuries
TAMPERE, Finland, Aug. 23, 2022 /PRNewswire/ — A recently published clinical study confirms the benefits of using fully bioresorbable ActivaPin™ implant together…
Read More » -
Sports Medicine
Bioretec enters into a distribution agreement with AMI Medical Technologies for bioresorbable Activa products in Israel
HELSINKI, May 12, 2022 /PRNewswire/ — Bioretec Ltd, a globally operating Finnish medical device company and a pioneer in bioresorbable orthopedic implants,…
Read More » -
Regulatory
Bioretec files for CE mark for its bioresorbable RemeOs magnesium screw in the EU
HELSINKI, Dec. 31, 2021 /PRNewswire/ — Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has submitted an application for the CE mark…
Read More »